Theracryf Plc · LSE:TCF

Theracryf — Evgen Pharma — Shareholder Meeting (July 2019)

16 slides from Theracryf's shareholder meeting presentation, Jul 18, 2019

  1. Slide 1: Evgen Pharma plc AGM Presentation

    EVGEN PHARMA PLC AGM Presentation 18 July 2019

  2. Slide 2: Disclaimer

    Disclaimer This document has been prepared by, and is the sole responsibility of Evgen Pharma plc (the "Company” or “Evgen”) which trades on the AIM market of the London Stock Exchange under ticker EVG. By attending this presentation and/or reviewing the slides, you agree to be bound by the followin

  3. Slide 3: Highlights of the year

    Highlights of the year  Clinical proof of concept clearly demonstrated in final top line data released from STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) Phase IIa clinical study  Dosing and three month visits completed in ongoing SAS (SFX-01 After Subarachnoid Haemorrh

  4. Slide 4: Recent placing and use of funds

    Recent placing and use of funds  Placing announced on 17 April 2019  Gross proceeds of £5m  Use of proceeds  to strengthen the balance sheet for future partnering;  developing product formulation for use in STEM II and other investigator-led clinical studies; and  conducting further toxicology

  5. Slide 5: Next steps and news flow

    Next steps and news flow  New development programmes associated with product formulation and expanded toxicology  Near-term news flow with regard to investigator-led clinical trials in new disease areas  STEM II clinical trial protocol in development and evaluation of access to non-dilutive capit

  6. Slide 6: Supplementary material for Q&A

    Supplementary material for Q&A

  7. Slide 7: STEM: SFX-01 treatment and evaluation in patients with metastatic breast cancer

    STEM: SFX-01 treatment and evaluation in patients with metastatic breast cancer

  8. Slide 8: Breast cancer is the most common cancer and the second most frequent cause of cancer death

    Breast cancer is the most common cancer and the second most frequent cause of cancer death in women  ER+ breast cancer is the most prevalent breast cancer sub-type (70%)  Metastatic breast cancer (MBC) means that the cancer has spread to other parts of the body  MBC is incurable with 5-year survi

  9. Slide 9: STEM, the first Phase II trial on SFX-01

    STEM, the first Phase II trial on SFX-01  Objectives - to evaluate the:  anti-tumour activity of SFX-01 after failure of at least one and up to three prior endocrine therapies  safety and tolerability in combination with the three commonly used endocrine approaches and with long-term exposure  O

  10. Slide 10: SFX-01 successfully met both primary endpoints

    SFX-01 successfully met both primary endpoints  Primary Endpoint 1: Clinical Benefit Rate (CBR, where CBR = Complete Response + Partial Response + Stable Disease) at 24 weeks using RECIST v1.1  SFX-01 can both stabilise and shrink endocrine resistant metastatic breast cancer  Primary Endpoint 2:

  11. Slide 11: An impressive clinical benefit rate in patients resistant to all endocrine therapies

    An impressive clinical benefit rate in patients that have become resistant to all endocrine therapies, and have advanced and progressive disease  Clinical Benefit Rate across all patients was c. 24%  Disease stabilisation seen in patients from all participating countries  Objective response seen

  12. Slide 12: Market opportunity for SFX-01 is initially second-line therapy post-CDK4/6i failure

    Market opportunity for SFX-01 is initially second-line therapy post-CDK4/6i failure Everolimus + Fulvestrant SFX-01 + Exemestane Fulvestrant Safety profile Poor Good Good (Target) Efficacy (Progression-Free Survival) 7.8 months 3 to 6 months > or = 7.8 months (Target) Sales Everolimus Fulvestrant SF

  13. Slide 13: SAS: SFX-01 After Subarachnoid Haemorrhage

    SAS: SFX-01 After Subarachnoid Haemorrhage

  14. Slide 14: Subarachnoid haemorrhage (SAH) accounts for approximately 5% of all strokes

    Subarachnoid haemorrhage (SAH) accounts for approximately 5% of all strokes  Defined by bleeding in the outer layers of the brain due to a ruptured brain aneurysm  40% of patients die within 30 days and for the survivors c.50% will have long-term cognitive impairment  A Delayed Cerebral Ischaemia

  15. Slide 15: SAS read-out projected for early Q4 of this calendar year

    SAS read-out projected for early Q4 of this calendar year  SAS: SFX-01 After Subarachnoid Haemorrhage – a Phase IIb, double-blind, placebo-controlled trial on 90 patients (45 in test and placebo arm respectively)  Administered alongside the calcium channel antagonist, nimodipine  Primary Endpoint

  16. Slide 16: Commercial opportunity: Potentially, the first drug approval in SAH since 1989

    Commercial opportunity: Potentially, the first drug approval in SAH since 1989  Estimated peak sales of c. $500m1 (c.f. $1.7bn projection for EG19622) as SAH orphan drug  Partner and/or co-develop post-Phase IIb (2019) to fund pivotal Phase III  Up-front payment potential post-Phase IIb of >$70m3

Evgen Pharma — Shareholder Meeting (July 2019) on 6ix